The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Biological Therapies for Inflammatory Bowel Diseases
Open accessAbstract
Crohn's disease and ulcerative colitis are chronic disabling inflammatory bowel diseases (IBDs). Although the causes of IBD are unknown, defects in innate and adaptive immune pathways have been identified and biological therapies that target key molecules have been designed. Infliximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody to tumor necrosis factor, dramatically improved treatment of patients with Crohn's disease and ulcerative colitis. Infliximab has achieved treatment goals such as mucosal healing and decreasing the need for hospitalizations and surgeries. Although several anti-tumor necrosis factor therapies have been developed, there is a great need for drugs that target other pathways. Natalizumab, an antibody against the integrin alpha4 subunit, blocks leukocyte adhesion and has reached the clinic in the United States but has not been approved in the European Union; other anti-adhesion molecules currently are under development. Additional approaches under clinical development include therapeutics that target cytokines, such as interleukin-12/23, as well as those that block T-cell signaling. The use of recombinant human proteins, including immunoregulatory cytokines and growth factors, has not been successful so far. The efficacy of each therapy must be shown in carefully designed clinical programs. Biological therapies carry a definite safety risk, so their place in treatment algorithms must be defined carefully.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Self-citationColombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Self-citationInflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationCyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A., Gelernt, I., Bauer, J., Galler, G., Michelassi, F., & Hanauer, S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,714
Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10
Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W., & Remaut, E. (2000) · Science · doi:10.1126/science.289.5483.1352 · Cited by 1,513
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
Self-citationFaubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Self-citationJärnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Self-citationProgressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Self-citationMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Self-citationSandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Self-citationComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Self-citationNatalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Self-citationMethotrexate for the Treatment of Crohn's Disease
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320503 · Cited by 911
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
Hyams, J., Crandall, W., Kugathasan, S., Griffiths, A., Olson, A., Johanns, J., Liu, G., Travers, S., Heuschkel, R., Markowitz, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.003 · Cited by 877
Anti–Interleukin-12 Antibody for Active Crohn's Disease
Mannon, P. J., Fuss, I. J., Mayer, L., Elson, C. O., Sandborn, W. J., Present, D., Dolin, B., Goodman, N., Groden, C., Hornung, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033402 · Cited by 848
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease
Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J., van Deventer, S. J. H., Neirynck, S., Peppelenbosch, M. P., & Steidler, L. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.028 · Cited by 786
Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.014 · Cited by 753
Self-citationA Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422202 · Cited by 727
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
Frequency of glucocorticoid resistance and dependency in Crohn's disease.
Munkholm, P., Langholz, E., Davidsen, M., & Binder, V (1994) · Gut · doi:10.1136/gut.35.3.360 · Cited by 654
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Self-citationMaser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Vermeire, S., Noman, M., Van Assche, G., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602
Self-citationLichtenstein, G. R., Yan, S., Bala, M., Blank, M., & Sands, B. E. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.048 · Cited by 597
Mackey, A. C., Green, L., Liang, L., Dinndorf, P., & Avigan, M. (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31802f6424 · Cited by 506
Ardizzone, S., Maconi, G., Russo, A., Imbesi, V, Colombo, E., & Bianchi Porro, G. (2006) · Gut · doi:10.1136/gut.2005.068809 · Cited by 505
Van Assche, G., Magdelaine–Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Watier, H., Paintaud, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.004 · Cited by 495
Self-citationFidder, H., Schnitzler, F., Ferrante, M., Noman, M., Katsanos, K., Segaert, S., Henckaerts, L., Van Assche, G., Vermeire, S., & Rutgeerts, P. (2009) · Gut · doi:10.1136/gut.2008.163642 · Cited by 449
Self-citationVan Assche, G., D’haens, G., Noman, M., Vermeire, S., Hiele, M., Asnong, K., Arts, J., D’hoore, A., Penninckx, F., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01214-9 · Cited by 448
Self-citationHommes, D., Van Den Blink, B., Plasse, T., Bartelsman, J., Xu, C., Macpherson, B., Tytgat, G., Peppelenbosch, M., & Van Deventer, S. (2002) · Gastroenterology · doi:10.1053/gast.2002.30770 · Cited by 378
Feagan, B. G., Panaccione, R., Sandborn, W. J., D'Haens, G. R., Schreiber, S., Rutgeerts, P. J., Loftus, E. V., Lomax, K. G., Yu, A. P., Wu, E. Q., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.069 · Cited by 374
Self-citationLÉmann, M., Mary, J., Duclos, B., Veyrac, M., Dupas, J., Delchier, J. C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.014 · Cited by 372
Sargramostim for Active Crohn's Disease
Korzenik, J. R., Dieckgraefe, B. K., Valentine, J. F., Hausman, D. F., & Gilbert, M. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041109 · Cited by 338
Sinha, A., Nightingale, J. M. D., West, K. P., Berlanga-Acosta, J., & Playford, R. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013136 · Cited by 303
Moskovitz, D. N., Van Assche, G., Maenhout, B., Arts, J., Ferrante, M., Vermeire, S., & Rutgeerts, P. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.001 · Cited by 297
Self-citationTreatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Hommes, D. W. (2005) · Gut · doi:10.1136/gut.2005.079392 · Cited by 238
Sandborn, W. J., Tremaine, W. J., Wolf, D. C., Targan, S. R., Sninsky, C. A., Sutherland, L. R., Hanauer, S. B., McDonald, J. W. D., Feagan, B. G., Fedorak, R. N., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70445-2 · Cited by 237
Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
Lewis, J. D., Lichtenstein, G. R., Deren, J. J., Sands, B. E., Hanauer, S. B., Katz, J. A., Lashner, B., Present, D. H., Chuai, S., Ellenberg, J. H., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.012 · Cited by 229
A Preliminary Study of Growth Hormone Therapy for Crohn's Disease
Slonim, A. E., Bulone, L., Damore, M. B., Goldberg, T., Wingertzahn, M. A., & McKinley, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422203 · Cited by 205
Schreiber, S., Feagan, B., D’Haens, G., Colombel, J., Geboes, K., Yurcov, M., Isakov, V., Golovenko, O., Bernstein, C. N., Ludwig, D., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.11.013 · Cited by 186
Reinisch, W., Hommes, D. W., Van Assche, G., Colombel, J.-F., Gendre, J.-P., Oldenburg, B., Teml, A., Geboes, K., Ding, H., Zhang, L., et al. (2006) · Gut · doi:10.1136/gut.2005.079434 · Cited by 175
Self-citationBorrelli, O., Bascietto, C., Viola, F., Bueno de Mesquita, M., Barbato, M., Mancini, V., Bosco, S., & Cucchiara, S. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.12.014 · Cited by 167
Assche, G. V., Sandborn, W. J., Feagan, B. G., Salzberg, B. A., Silvers, D., Monroe, P. S., Pandak, W. M., Anderson, F., Valentine, J. F., Wild, G., et al. (2006) · Gut · doi:10.1136/gut.2005.089854 · Cited by 143
Self-citationPlevy, S. E., Salzberg, B. A., Assche, G. V., Regueiro, M. D., Hommes, D. W., Sandborn, W. J., Hanauer, S. B., Targan, S. R., Mayer, L., Mahadevan, U., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.035 · Cited by 143
Assche, G. V., Dalle, I., Noman, M., Aerden, I., Swijsen, C., Asnong, K., Maes, B., Ceuppens, J. L., Geboes, K. J., & Rutgeerts, P. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07239.x · Cited by 127
Self-citationRdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis
Travis, S. P. L., Yap, L. M., Hawkey, C., Warren, B. F., Lazarov, M. E., Fong, T., & Tesi, R. J. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000172807.26748.16 · Cited by 121
Thayu, M., Leonard, M. B., Hyams, J. S., Crandall, W., Kugathasan, S., Otley, A. R., Olson, A. D., Johanns, J., Marano, C. W., Heuschkel, R. B., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.07.010 · Cited by 116
Sandborn, W. J., Sands, B. E., Wolf, D. C., Valentine, J. F., Safdi, M. A., Katz, S., Isaacs, K. L., Wruble, L. D., Katz, J., Present, D. H., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01589.x · Cited by 115
Burakoff, R. B., Barish, C. F., Riff, D. S., Pruitt, R. E., Chey, W. Y., Farraye, F. A., Shafran, I., Katz, S., Krone, C. L., Vliet, M. V., et al. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.ibd.0000225337.14356.31 · Cited by 112
CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.
Stronkhorst, A., Radema, S. A., Yong, S. L., Bijl, H. M., ten Berge, I. J. M., Tytgat, G. N. J., & van Deventer, S. J. H. (1997) · Gut · doi:10.1136/gut.40.3.320 · Cited by 107
CREED, T. J., PROBERT, C. S. J., NORMAN, M. N., MOORGHEN, M., SHEPHERD, N. A., HEARING, S. D., DAYAN, C. M., & THE BASBUC INVESTIGATORS (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02904.x · Cited by 101
Kasran, A., Boon, L., Wortel, C. H., van Hogezand, R. A., Schreiber, S., Goldin, E., BOER, M. D., Geboes, K., Rutgeerts, P. J., & Ceuppens, J. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02526.x · Cited by 85
Self-citationRutgeerts, P., Sandborn, W. J., Fedorak, R. N., Rachmilewitz, D., Tarabar, D. K., Gibson, P. G., Nielsen, O. H., Wild, G., Schreiber, S., Rossi, C. P., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.022 · Cited by 67
Self-citationPeña-Rossi, C., Schreiber, S., Golubović, G., Mertz-Nielsen, A., Panés, J., Rachmilewitz, D., Shieh, M., Simanenkov, V., Stanton, D., & Graffner, H. (2008) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.2008.03778.x · Cited by 52
Cited by
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationDanese, S., & Fiocchi, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1102942 · Cited by 1,102
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
DʼHaens, G., Ferrante, M., Vermeire, S., Baert, F., Noman, M., Moortgat, L., Geens, P., Iwens, D., Aerden, I., Van Assche, G., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22917 · Cited by 816
Self-citationMedical Micro/Nanorobots in Precision Medicine
Soto, F., Wang, J., Ahmed, R., & Demirci, U. (2020) · Advanced Science · doi:10.1002/advs.202002203 · Cited by 442
Metadata
- Authors
- Rutgeerts, P., Vermeire, S., & Van Assche, G.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 136
- Issue
- 4
- Pages
- 1182-1197
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2053303708
- Cited by
- 363
- References
- 69
- FWCI
- 29.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.